Regional Quantitative Magnetic Resonance Imaging Data Improve Screening Accuracy of Subjective Memory Complaints and Informant Reports of Cognitive Decline

Article information

Psychiatry Investig. 2020;17(9):851-857

Publication date (electronic) : 2020 September 17

doi : https://doi.org/10.30773/pi.2020.0323

Seon Jin Yim ¹

, Dahyun Yi ²

, Min Soo Byun ²

, Kiyoung Sung ³

, Dong Young Lee^,²^,³^,⁴

¹Department of Geriatric Psychiatry, National Center for Mental Health, Seoul, Republic of Korea

²Institute of Human Behavioral Medicine, Medical Research Center Seoul National University, Seoul, Republic of Korea

³Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea

⁴Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence: Dong Young Lee, MD, PhD Department of Neuropsychiatry, Seoul National University Hospital, Department of Psychiatry, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea Tel: +82-2-2072-2205, Fax: +82-2-744-7241, E-mail: selfpsy@snu.ac.kr

Received 2020 August 26; Accepted 2020 September 7.

Abstract

Objective

We investigated whether the addition of Alzheimer’s disease-signature region cortical thickness (AD-Ct) and hippocampal volume (Hv) obtained from brain MRI to subjective memory complaints and informant-reports of cognitive decline enhances the screening accuracy for cognitive disorders in a memory clinic setting.

Methods

120 participants (40 cognitively normal, 40 MCI, 40 dementia) underwent clinical evaluation, neuropsychological assessment, and brain MRI. The Subjective Memory Complaints Questionnaire (SMCQ) and Seoul Informant-Report Questionnaire for Dementia (SIRQD) were applied to assess subjective memory complaints and informant-reports of cognitive decline respectively. Logistic regression and ROC curve analyses were conducted to compare the screening abilities of SMCQ+SIRQD, SMCQ+SIRQD+Hv, and SMCQ+SIRQD+AD-Ct models for cognitive disorders.

Results

SMCQ+SIRQD+Hv model indicated better screening accuracy for MCI and overall cognitive disorder (CDall) than SMCQ+ SIRQD model. SMCQ+SIRQD+AD-Ct model had superior screening accuracy for dementia in comparison to SMCQ+SIRQD model. ROC curve analyses revealed that SMCQ+SIRQD+Hv model had the greatest area under the curve (AUC) for screening MCI and CDall (AUC: 0.941 and 0.957), while SMCQ+SIRQD+AD-Ct model had the greatest AUC for screening dementia (AUC: 0.966).

Conclusion

Our results suggest that the addition of regional quantitative MRI data enhances the screening ability of subjective memory complaints and informant-reports of cognitive decline for MCI and dementia.

Keywords: Cognitive disorder; Screening; Subjective memory complaint; Informant report; MRI

INTRODUCTION

Subjective memory complaints and informant reports of cognitive decline are routinely checked in the memory clinic setting, and both are repeatedly reported as important predictors of cognitive disorders including mild cognitive impairment (MCI) and dementia [1-8]. Despite the evidence, limitations still exist in predicting cognitive disorder only from subjective memory complaints and informant reports of cognitive decline.

Brain magnetic resonance imagining (MRI) is commonly performed in the memory clinic for the differential diagnosis of cognitive disorders. Certain findings on brain MRI are also known to be useful in the screening of cognitive disorders or predicting switch to dementia from mild cognitive impairment [9-11]. Hippocampal atrophy is frequently observed not only in MCI [11,12] and Alzheimer’s disease (AD) dementia [12-15], but also in vascular and fronto-temporal dementia (FTD) [9,10,16]. Cortical atrophy in different brain regions is common in various cognitive disorders including MCI, AD dementia, Parkinson’s disease dementia, and FTD [11,12,17-20]. Moreover, the severity of hippocampal or cortical atrophy are reported to have a clear relationship with the severity of cognitive decline [12-15]. However, very few studies investigated the usefulness of quantitative information from brain MRI in improving the screening ability of subjective memory complaints and informant reports of cognitive decline for cognitive disorders.

The aim of this study was to investigate whether the supplementation of hippocampal volume (Hv) and AD-signature region cortical thickness (AD-Ct) data obtained from the brain MRI to subjective memory complaints and informant reports of cognitive decline can enhance the screening ability for cognitive disorders in a memory clinic setting.

METHODS

Participants

One hundred and twenty individuals participated in this study at the dementia clinic of Seoul National University Hospital. All participants were aged between 65 to 80 years, divided into age-, sex-, and education-matched groups of 40 cognitively normal (CN) individuals, 40 with mild cognitive impairment (MCI), and 40 with dementia (AD).

The criteria of the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [21] was the basis for diagnosis of dementia, and the probable or possible AD criteria of the National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) [22] for that of AD. A diagnosis of MCI was made according to the Peterson criteria [23].

The following participants were excluded: 1) individuals with major medical, psychiatric, or neurological conditions affecting cognitive function, 2) individuals with communication or behavioral problems making clinical assessment difficult, 3) individuals without a reliable informant, and 4) individuals with limited reading ability of Korean making neuropsychological assessment difficult. Individuals with minor physical conditions, such as mild hearing loss, essential hypertension, and diabetes with no serious complication, were included in this study.

This study was ethically approved by Seoul National University/Seoul National University Hospital Institional Review Board (IRB No. H-2006-101-1132).

Clinical and neuropsychological assessment

All participants were assessed by psychiatrists with advanced training in dementia research with the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K) clinical assessment battery [24].

The cognitive function of participants was tested by trained clinical psychologists using the CERAD-K neuropsychological battery [25]. The CERAD-K neuropsychological battery consists of the 15-item Boston Naming Test, Word List Memory, Word List Recall, Word List Recognition, Constructional Praxis, Constructional Recall, and Mini-Mental State Examination (MMSE).

A panel of four or more psychiatrists, experts in dementia research verified the diagnosis through integrating examination and discussion of all available raw data.

Assessment of subjective memory complaints and informant reports of cognitive decline

Subjective memory complaints of all participants were measured by the Subjective Memory Complaints Questionnaire (SMCQ) [5] and informant reports of cognitive decline were assessed using the Seoul Informant Report Questionnaire for Dementia (SIRQD) [26]. The SMCQ is a self-reported questionnaire for elderly to report their memory problems in general and in daily living and consists of 14 items with a maximum score of 14. The SMCQ is known for its reasonable reliability and validity showing significant associations with objective cognitive impairment, which was using neuropsychological batteries [5]. The SIRQD is an informant questionnaire which consists of 15 items with a maximum score of 30. The SIRQD takes a short questionnaire and efficiently provides essential information about a patient’s cognitive impairment. It has also been proven to be reliable and valid, and especially shows a low likelihood of false positives and false negatives when applied to the elderly with a wide range of educational level, as found in the Korean elderly population [26].

Acquisition and processing of brain MRI

Brain MRI was obtained via a 3.0-T whole body imaging system (GE VH/I; General Electric, Milwaukee, WI, USA). A three-dimensional T1-weighted SPGR (spoiled gradient recalled echo) sequence was obtained (TR=22 ms, TE=4 ms, slice flip angle=40°). The obtained T1-weighted image was processed by FreeSurfer version 5.3 (http://surfer.nmr.mgh.harvard.edu/), and cortical thickness, intracranial volume, and Hv were calculated in accordance with the Desikan-Killiany atlas [27].

FreeSurfer is a software package used to analyze of neuroimaging data in order to provide an array of algorithms to quantify the functional, connectional, and structural properties of the human brain using T1-weighted input images [28].

AD-Ct was defined as the average cortical thickness of the regions which are known to be related to AD dementia [29] including the rostral medial temporal lobe (localized to the crown of the parahippocampal gyrus in the region of the uncal hippocampal formation, extending into the collateral sulcus), inferior temporal gyrus, temporal pole, angular gyrus, superior frontal gyrus, superior parietal lobule, supramarginal gyrus, posterior cingulate/precuneus, and middle frontal gyrus. Hv was calculated by summing right and left extracted Hv. To correct for differences in intracranial volumes between participants, the value of the hippocampal volume divided by the intracranial volume derived from FreeSurfer was used in statistical analyses.

Statistical analysis

Between-group comparisons of demographic and clinical data were looked into using the two-tailed t-test and χ² test. Logistic regression analyses were applied to examine the abilities of the SMCQ, SIRQD, SMCQ+SIRQD, SMCQ+SIRQD+ Hv, and SMCQ+SIRQD+AD-Ct models to distinguish between three different cognitive disorder groups, i.e., MCI, dementia, and overall cognitive disorder (CDall) groups (MCI and dementia). Differences of -2 log likelihood (-2LL) were utilized for comparison of the predictive ability of the SMCQ, SIRQD, SMCQ+SIRQD, SMCQ+SIRQD+Hv, and SMCQ+SIRQD+ AD-Ct models. Receiver operating characteristic (ROC) curve analyses were also performed for comparing the screening accuracy of the models and the areas under curve (AUC) of ROC were compared using the method of Hanley and McNeil [30]. The score for the ROC curve analysis was calculated as the sum of each variable multiplied by the respective β coefficient from the logistic regression model.

RESULTS

Demographic and clinical characteristics

There was no significant between-group difference in age, education, or sex. CN had significantly lower SMCQ and SIRQD scores, and higher Hv value than individuals with MCI or dementia. The CN group also had significantly higher AD-Ct value than the dementia group, but no such difference in the AD-Ct value was found between CN and MCI groups (Table 1). Twenty-seven (67.5%) subjects had AD among the dementia patients, and 35 (87.5%) had amnestic MCI among the MCI individuals.

Table 1.

Demographic and clinical characteristics of subjects with brain MRI

Logistic regression analysis and the differences of -2 log likelihood

Compared to the SMCQ only or SIRQD only model, the SMCQ+SIRQD model had superior screening ability for any cognitive disorders (i.e., CDall, MCI, or dementia) (Table 2). The SMCQ+SIRQD+Hv model had better screening accuracy for MCI and CDall, but not for dementia, than the SMCQ+ SIRQD model. In contrast, the SMCQ+SIRQD+AD-Ct model had better ability for screening dementia, but not for screening MCI or CDall, than the SMCQ+SIRQD model (Table 2).

Table 2.

Results obtained from logistic regression analysis designed to compare the screening ability of different models

ROC curve analysis

Similar to the results from the direct comparison of logistic regression models, ROC curve analyses showed that the SMCQ+SIRQD+Hv model had the greatest AUC among models for screening MCI and CDall (AUC: 0.941 and 0.957, respectively), while the SMCQ+SIRQD+AD-Ct model had the greatest AUC among models for screening dementia (AUC: 0.966) (Table 3, Figure 1).

Table 3.

Area under curves (AUC) and SMCQ, SIRQD, SMCQ+SIRQD, SMCQ+SIRQD+Hv, and SMCQ+SIRQD+AD-Ct cut-off scores for MCI, dementia, and overall cognitive impairment

Figure 1.

Receiver operating characteristic (ROC) curves for the Subjective Memory Complaints Questionnaire (SMCQ), Seoul Informant Report Questionnaire for Dementia (SIRQD), SIRQD-supplemented SMCQ (SMCQ+SIRQD), adjusted hippocampal volume-supplemented SMCQ+SIRQD (SMCQ+SIRQD+Hv), and AD-signature region cortical thickness-supplemented SMCQ+SIRQD (SMCQ+SIRQD+AD-Ct) in screening for (A) cognitively normal (CN), versus mild cognitive impairment (MCI), (B) CN versus dementia, and (C) CN versus overall cognitive disorder (MCI+dementia).

DISCUSSION

In this study, we investigated whether the supplementation of hippocampal volume and cortical thickness data obtained from brain MRI can improve the predictive ability of subjective memory complaints and informant reports of cognitive decline for cognitive disorders in the memory clinic environment. The results show that adding the Hv data significantly improved the accuracy of the SMCQ plus SIRQD model for screening MCI and CDall, while adding the AD-Ct data to the model improved its accuracy for screening dementia. This study is novel in that it revealed the clear usefulness of quantitative brain MRI data in improving the screening ability of subjective complaints and informant reports. Moreover, our study demonstrated that such combinations of information commonly obtained from memory clinic practice could very accurately predict MCI and dementia (AUC: up to 0.941 for MCI and 0.966 for dementia as shown in Table 3).

The hippocampus is one of the first affected brain areas in AD and its volume reduction is observed even before the clinical dementia stage [29,31,32] or even in the cognitively asymptomatic stage [33]. Several studies also showed that Hv reduction was observed in the pre-dementia stage of non-AD dementing diseases such as frontotemporal lobar degeneration, cerebrovascular disease, Parkinson’s disease, and diffuse Lewy body disease [34-37]. Such earlier reduction in Hv may explain our finding that adding Hv information to SMCQ plus SIRQD significantly enhanced the screening accuracy for MCI and CDall.

Our study showed that supplementation of AD-Ct information significantly improved the dementia screening ability of the SMCQ plus SIRQD model, whereas adding Hv information did not. The resulting SMCQ+SIRQD+AD-Ct model also had the highest accuracy in screening for dementia, while the SMCQ+SIRQD+Hv model showed the highest accuracy for screening MCI and CDall, but not dementia. A reduction in cortical thickness is observed in various dementing neurodegenerative diseases including AD [11,12,17-20,29,38] and is closely related to the worsening of cognitive symptoms [29,39]. Moreover, cortical atrophy reflects later stages of pathological changes (Braak stage IV–V) in AD, while hippocampal atrophy relates to earlier stages (Braak stage II–III) [40]. This may explain our finding of the specific benefit of adding the AD-Ct data to SMCQ and SIRQD in screening for dementia.

Limitations of this study are as followes: 1) as the sample size was not sufficiently large, we did not perform subgroup analyses according to the type or cause of cognitive disorders. 2) this is a cross-sectional study and focused on screening for current cognitive disorders. Further longitudinal studies should be conducted to examine the benefit of adding MRI information in predicting the progression of cognitive disorders. 3) Supplementation of regional quantitative brain MRI information requires a time-consuming MR processing for the quantification of AD-Ct or Hv as well as an additional cost for MRI. Easier and less-time consuming method to obtain quantitative information for cortical or hippocampal atrophy needed to be developed.

In conclusion, our results suggest that the supplementation of regional quantitative MRI information can improve the screening accuracy of subjective memory complaints and informant reports of cognitive decline for cognitive disorders. More specifically, adding hippocampal volume and cortical thickness information appears to enhance screening MCI and dementia, respectively.

Acknowledgements

This study was supported by a grant from the Ministry of Science and ICT, Republic of Korea (Grant No. NRF-2014M3C7A1046042) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0630 & HI19C0149).

Notes

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Dong Young Lee. Data curation: Dahyun Yi. Formal analysis: Seon Jin Yim. Funding acquisition: Dong Young Lee. Investigation: Seon Jin Yim, Min Soo Byun. Methodology: Dahyun Yi. Project administration: Seon Jin Yim, Min Soo Byun. Resources: Kiyoung Sung. Software: Dahyun Yi, Kiyoung Sung. Supervision: Dong Young Lee. Validation: Seon Jin Yim. Visualization: Kiyoung Sung. Writing—original draft: Seon Jin Yim. Writing—review & editing: Dong Young Lee.

References

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270–279.

2. Jessen F. Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 2014;264(Suppl 1):S3–7.

3. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement 2014;10:844–852.

4. Wang L, van Belle G, Crane PK, Kukull WA, Bowen JD, McCormick WC, et al. Subjective memory deterioration and future dementia in people aged 65 and older. J Am Geriatr Soc 2004;52:2045–2051.

5. Youn JC, Kim KW, Lee DY, Jhoo JH, Lee SB, Park JH, et al. Development of the subjective memory complaints questionnaire. Dement Geriatr Cogn Disord 2009;27:310–317.

6. Carr DB, Gray S, Baty J, Morris JC. The value of informant versus individual’s complaints of memory impairment in early dementia. Neurology 2000;55:1724–1726.

7. Cherbuin N, Anstey KJ, Lipnicki DM. Screening for dementia: a review of self- and informant-assessment instruments. Int Psychogeriatr 2008;20:431–458.

8. Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med 1994;24:145–153.

9. Eckerstrom C, Olsson E, Klasson N, Bjerke M, Gothlin M, Jonsson M, et al. High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement Geriatr Cogn Disord 2011;31:132–138.

10. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55:335–346.

11. Hamalainen A, Tervo S, Grau-Olivares M, Niskanen E, Pennanen C, Huuskonen J, et al. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Neuroimage 2007;37:1122–1131.

12. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2004;23:708–716.

13. Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol 2008;255:567–574.

14. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)- scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559–567.

15. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71:743–749.

16. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation 2012;125:37–44.

17. Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, et al. Different regional patterns of cortical thinning in alzheimer’s disease and frontotemporal dementia. Brain 2007;130:1159–1166.

18. Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain 2014;137:1120–1129.

19. Lyoo CH, Ryu YH, Lee MS. Topographical distribution of cerebral cortical thinning in patients with mild Parkinson’s disease without dementia. Mov Disord 2010;25:496–499.

20. Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, et al. Thinning of the cerebral cortex in aging. Cereb Cortex 2004;14:721–730.

21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Washington DC: American Psychiatric Publishing; 1994.

22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.

23. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.

24. Lee JH, Lee KU, Lee DY, Kim KW, Jhoo JH, Kim JH, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci 2002;57:P47–P53.

25. Lam LC, Lui VW, Tam CW, Chiu HF. Subjective memory complaints in Chinese subjects with mild cognitive impairment and early Alzheimer’s disease. Int J Geriatr Psychiatry 2005;20:876–882.

26. Lee DY, Kim KW, Yoon JC, Jhoo JH, Lee JH, Woo JI. Development of an informant report questionnaire for dementia screening: Seoul Informant Report Questionnaire for Dementia(SIRQD). J Korean Neuropsychiatr Assoc 2004;43:209–217.

27. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–980.

28. Fischl B. FreeSurfer. Neuroimage 2012;62:774–781.

29. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009;19:497–510.

30. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839–843.

31. van der Flier WM, van Straaten EC, Barkhof F, Ferro JM, Pantoni L, Basile AM, et al. Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry 2005;76:1497–1500.

32. Shi F, Liu B, Zhou Y, Yu C, Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer’s disease: meta-analyses of MRI studies. Hippocampus 2009;19:1055–1064.

33. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer’s disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci 2013;33:5553–5563.

34. Double KL, Halliday GM, McRitchie DA, Reid WG, Hely MA, Morris JG. Regional brain atrophy in idiopathic parkinson’s disease and diffuse Lewy body disease. Dementia 1996;7:304–313.

35. Frisoni GB, Laakso MP, Beltramello A, Geroldi C, Bianchetti A, Soininen H, et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and alzheimer’s disease. Neurology 1999;52:91–100.

36. Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, Karnos T, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997;48:1297–1304.

37. Laakso MP, Partanen K, Riekkinen P, Lehtovirta M, Helkala EL, Hallikainen M, et al. Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996;46:678–681.

38. Whitwell JL, Josephs KA, Rossor MN, Stevens JM, Revesz T, Holton JL, et al. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol 2005;62:1402–1408.

39. Bonifacio G, Zamboni G. Brain imaging in dementia. Postgrad Med J 2016;92:333–340.

40. Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer’s disease related cortical lesions. J Neural Transm Suppl 1998;54:97–106.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

	CN (N=40)	MCI (N=40)	D (N=40)	CDall (N=40)	p value
Age (years)^*	71.65±4.50	73.03±4.39	72.93±4.35	72.98±4.35	0.171	0.468	0.122
Education (years)^*	11.98±3.79	11.18±3.98	11.00±3.86	11.09±3.90	0.360	0.587	0.238
Women (%)^†	50	50	50	50	1.000	1.000	1.000
SMCQ^*	3.05±3.02	6.12±3.35	8.35±3.53	7.24±3.59	<0.001	<0.001	<0.001
SIRQD^*	5.00±3.79	9.17±4.81	19.61±6.72	15.07±7.89	0.003	<0.001	<0.001
Hv^*	0.0051±0.0006	0.0046±0.0008	0.0043±0.0011	0.0044±0.0009	0.003	<0.001	<0.001
AD-Ct^*	2.50±0.19	2.51±0.14	2.07±0.24	2.29±0.29	0.776	<0.001	<0.001

Table 2.

Results obtained from logistic regression analysis designed to compare the screening ability of different models

Models	Screening accuracy (%)	χ²	-2LL	df	p value	Significance test for -2LL difference
CN vs. CDALL
SMCQ	78.3	35.610	117.154	1	<0.001^*	SMCQ vs. SMCQ+SIRQD: p<0.001^*
SIRQD	80.5	28.090	60.618	1	<0.001^*	SIRQD vs. SMCQ+SIRQD: p=0.001^*
SMCQ+SIRQD	86.2	43.963	44.745	2	<0.001^*	SMCQ+SIRQD vs.+HV: p=0.007^*
SMCQ+SIRQD+Hv	90.8	51.173	37.535	3	<0.001^*	SMCQ+SIRQD vs.+AD-Ct: p=0.128
SMCQ+SIRQD+AD-Ct	88.5	46.278	42.430	3	<0.001^*
CN vs. MCI
SMCQ	70.0	16.770	94.133	1	<0.001^*	SMCQ vs. SMCQ+SIRQD: p<0.001^*
SIRQD	72.9	9.443	54.067	1	0.002^*	SIRQD vs. SMCQ+SIRQD: p<0.001^*
SMCQ+SIRQD	79.2	23.938	39.572	2	<0.001^*	SMCQ+SIRQD vs.+Hv: p=0.004^*
SMCQ+SIRQD+Hv	85.4	35.403	31.107	3	<0.001^*	SMCQ+SIRQD vs.+AD-Ct: p=0.346
SMCQ+SIRQD+AD-Ct	81.3	24.825	38.685	3	<0.001^*
CN vs. D
SMCQ	70.8	25.975	126.827	1	<0.001^*	SMCQ vs. SMCQ+SIRQD: p<0.001^*
SIRQD	81.6	57.739	61.936	1	<0.001^*	SIRQD vs. SMCQ+SIRQD: p<0.114
SMCQ+SIRQD	86.2	60.230	59.445	2	<0.001^*	SMCQ+SIRQD vs.+Hv: p=0.478
SMCQ+SIRQD+Hv	85.1	60.733	59.942	3	<0.001^*	SMCQ+SIRQD vs.+AD-Ct: p=0.001^*
SMCQ+SIRQD+AD-Ct	92.0	80.760	38.915	3	<0.001^*

p<0.05.

-2LL indicates the -2 log likelihood, SMCQ: Subjective Memory Complaints Questionnaire, SIRQD: the Seoul Informant Report Questionnaire for Dementia, Hv: adjusted hippocampal volume, AD-Ct: AD-signature region cortical thickness, SMCQ+SIRQD: SIRQD supplemented SMCQ, SMCQ+SIRQD+Hv: Hv supplemented SMCQ+SIRQD, SMCQ+SIRQD+AD-Ct: AD-signature region cortical thickness supplemented SMCQ+SIRQD, CN: cognitively normal, D: dementia, CDall: overall cognitive disorder (MCI+D)

Table 3.

Area under curves (AUC) and SMCQ, SIRQD, SMCQ+SIRQD, SMCQ+SIRQD+Hv, and SMCQ+SIRQD+AD-Ct cut-off scores for MCI, dementia, and overall cognitive impairment

	CN vs. MCI (N=80)	CN vs. D (N=80)	CN vs. CDall (N=120)
SMCQ
AUC	0.858	0.792	0.907
SE	0.0533	0.0485	0.0327
95% CI	0.727–0.942	0.692–0.872	0.825–0.958
Cut off	3/4	6/7	3/4
Sen/spe	77.5/67.5	72.5/72.5	83.7/67.5
SIRQD
AUC	0.754	0.919^*	0.869
SE	0.0730	0.0321	0.0410
95% CI	0.608–0.867	0.841–0.967	0.779–0.932
Cut off	7/8	16/17	10/11
Sen/spe	60.0/83.3	74.4/95.8	69.6/94.4
SMCQ+SIRQD
AUC	0.875	0.930^*	0.933
SE	0.0501	0.0302	0.0256
95% CI	0.748–0.953	0.854–0.973	0.858–0.975
Cut off	12/13	22/23	12/13
Sen/spe	63.3/94.4	82.1/91.7	81.2/94.4
SMCQ+SIRQD+Hv
AUC	0.941^*†	0.927^*	0.957^*†
SE	0.0348	0.0307	0.0200
95% CI	0.832–0.988	0.850–0.972	0.890–0.0989
Pr (case)	≥0.3	≥0.5	≥0.5
Sen/spe	85.0/82.5	82.5/92.5	87.5/85.0
SMCQ+SIRQD+AD-Ct
AUC	0.878^†	0.966^*†‡	0.928
SE	0.0494	0.0162	0.0267
95% CI	0.751–0.954	0.904–0.993	0.852–0.973
Pr (case)	≥0.5	≥0.4	≥0.5
Sen/spe	75.0/82.5	92.5/93.7	83.7/85.0

significantly greater than that of SMCQ,

^†

significantly greater than that of SIRQD,

^‡

significantly greater than that of SMCQ+SIRQD+Hv (tested by Hanley and McNeil’s method).

CN: cognitively normal, MCI: mild cognitive impairment, D: dementia, CDall: overall cognitive disorder, SMCQ: Subjective Memory Complaints Questionnaire, SIRQD: Seoul Informant Report Questionnaire for Dementia, SMCQ+SIRQD: SIRQD supplemented SMCQ, SMCQ+SIRQD+Hv: Hv supplemented SMCQ+SIRQD, SMCQ+SIRQD+AD-Ct: AD-signature region cortical thickness supplemented SMCQ+SIRQD